These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26992147)

  • 41. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist.
    Naruhn S; Meissner W; Adhikary T; Kaddatz K; Klein T; Watzer B; Müller-Brüsselbach S; Müller R
    Mol Pharmacol; 2010 Feb; 77(2):171-84. PubMed ID: 19903832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
    Hollingshead HE; Borland MG; Billin AN; Willson TM; Gonzalez FJ; Peters JM
    Carcinogenesis; 2008 Jan; 29(1):169-76. PubMed ID: 17893232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions.
    Wagner KD; Wagner N
    Pharmacol Ther; 2010 Mar; 125(3):423-35. PubMed ID: 20026355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ.
    Wu CC; Baiga TJ; Downes M; La Clair JJ; Atkins AR; Richard SB; Fan W; Stockley-Noel TA; Bowman ME; Noel JP; Evans RM
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2563-E2570. PubMed ID: 28320959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective role of peroxisome proliferator-activated receptor-β/δ against pulmonary oxygen toxicity mediated through changes in NOS expression levels.
    Bao XC; Fang YQ; You P; Zhang S; Ma J
    Exp Lung Res; 2014 Apr; 40(3):105-16. PubMed ID: 24624894
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies towards the conception of new selective PPARbeta/delta ligands.
    Basséne CE; Suzenet F; Hennuyer N; Staels B; Caignard DH; Dacquet C; Renard P; Guillaumet G
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4528-32. PubMed ID: 16797985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.
    Bility MT; Devlin-Durante MK; Blazanin N; Glick AB; Ward JM; Kang BH; Kennett MJ; Gonzalez FJ; Peters JM
    Carcinogenesis; 2008 Dec; 29(12):2406-14. PubMed ID: 18799709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
    Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.
    Borland MG; Foreman JE; Girroir EE; Zolfaghari R; Sharma AK; Amin S; Gonzalez FJ; Ross AC; Peters JM
    Mol Pharmacol; 2008 Nov; 74(5):1429-42. PubMed ID: 18687807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
    Coll T; Rodrïguez-Calvo R; Barroso E; Serrano L; Eyre E; Palomer X; Vázquez-Carrera M
    Curr Mol Pharmacol; 2009 Jan; 2(1):46-55. PubMed ID: 20021445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
    Hollingshead HE; Killins RL; Borland MG; Girroir EE; Billin AN; Willson TM; Sharma AK; Amin S; Gonzalez FJ; Peters JM
    Carcinogenesis; 2007 Dec; 28(12):2641-9. PubMed ID: 17693664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PPAR-β/δ activation promotes phospholipid transfer protein expression.
    Chehaibi K; Cedó L; Metso J; Palomer X; Santos D; Quesada H; Naceur Slimane M; Wahli W; Julve J; Vázquez-Carrera M; Jauhiainen M; Blanco-Vaca F; Escolà-Gil JC
    Biochem Pharmacol; 2015 Mar; 94(2):101-8. PubMed ID: 25662586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.
    Rodríguez-Calvo R; Serrano L; Coll T; Moullan N; Sánchez RM; Merlos M; Palomer X; Laguna JC; Michalik L; Wahli W; Vázquez-Carrera M
    Diabetes; 2008 Aug; 57(8):2149-57. PubMed ID: 18443198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta.
    Degenhardt T; Saramäki A; Malinen M; Rieck M; Väisänen S; Huotari A; Herzig KH; Müller R; Carlberg C
    J Mol Biol; 2007 Sep; 372(2):341-55. PubMed ID: 17669420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
    Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S
    Future Cardiol; 2017 May; 13(3):279-296. PubMed ID: 28581362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of the peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) cistrome reveals novel co-regulatory role of ATF4.
    Khozoie C; Borland MG; Zhu B; Baek S; John S; Hager GL; Shah YM; Gonzalez FJ; Peters JM
    BMC Genomics; 2012 Nov; 13():665. PubMed ID: 23176727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishing the Role of PPARβ/δ in Carcinogenesis.
    Peters JM; Gonzalez FJ; Müller R
    Trends Endocrinol Metab; 2015 Nov; 26(11):595-607. PubMed ID: 26490384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PPARβ/δ and lipid metabolism in the heart.
    Palomer X; Barroso E; Zarei M; Botteri G; Vázquez-Carrera M
    Biochim Biophys Acta; 2016 Oct; 1861(10):1569-78. PubMed ID: 26825692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.